huahaipharm(SH:600521)2024-04-15 09:16Financial Performance Expectations - Zhejiang Huahai Pharmaceutical Co., Ltd. expects Q1 2024 net profit attributable to shareholders to be between CNY 259.5 million and CNY 285.5 million, an increase of approximately CNY 86.57 million to CNY 112.57 million, representing a year-on-year growth of about 50% to 65%[3]. - The company's Q1 2024 net profit attributable to shareholders after deducting non-recurring gains and losses is expected to be between CNY 292.2 million and CNY 320.5 million, an increase of approximately CNY 103.65 million to CNY 131.95 million, representing a year-on-year growth of about 55% to 70%[3]. - In the same period last year, the net profit attributable to shareholders was CNY 172.93 million, and the net profit after deducting non-recurring gains and losses was CNY 188.55 million[5]. Factors Contributing to Profit Growth - The significant increase in net profit is attributed to the continuous introduction and gradual increase in sales of new products, initial success in market expansion, and enhanced customer loyalty[6]. - The company has optimized lean management and improved technical transformation capabilities, further enhancing cost control and overall strength[6]. - The company has made adjustments to its sales team and organizational structure, extending market management efforts and actively exploring emerging markets[6]. Earnings Forecast Reliability - There are no major uncertainties affecting the accuracy of this earnings forecast[7]. - The earnings forecast data is preliminary and the specific financial data will be disclosed in the official Q1 2024 report[7].